9-substituted-8-unsubstituted-9-deazaguanines
CA 2047216 C · Owner: Ealick, Steven E. · Inventors: Erion, Mark D.; Ealick, Steven E.; Secrist, John A. Iii
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The specification discloses the compounds of formula (1) wherein (a) -CH2Ar represents formula .alpha. in which R1 represents hydrogen, halogen, C1-C3-alkyl, C1-C3-alkoxy benzyloxy, hydroxy, or trifluoromethyl; and R2 represents hydrogen halogen, C1-C3-alkyl, C1-C3-alkoxy, benzyloxy hydroxy or trifluoromethyl; provided that R2 represents hydrogen or C1-C3-alkyl if R1 represents trifluoromethyl or that R1 represents hydrogen or C1-C3-alkyl if R2 represents trifluoromethyl; or (b) -CH2Ar represents formula .beta. in which X represents sulfur or oxygen and in which attachment to the thiophene or furan ring is at the 2- or 3-position; and tautomers thereof; as purine nucleoside phosphorylase …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 27, 1990 and granted March 30, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.